Respiratory & Pulmonary Health Updates: New COPD Inhalers, Phage Therapy Breakthroughs, and a $10B Pharma Deal 🫁🚀
In this week’s Respiratory and Pulmonary Health Updates, we’re diving into the biggest headlines in respiratory science from promising phage therapy results and a major biopharma acquisition to China’s evolving COPD treatment landscape and real-world innovation in nasal sprays and biologics.
🔬 Lupin Launches Ipratropium Bromide Nasal Spray in the U.S.
Lupin introduces a bioequivalent to Atrovent®, now available in two strengths. With a U.S. market valued at $63 million annually, this launch addresses rhinorrhea from allergies and the common cold.
🧪 Upstream Bio Begins Phase 2 Trial of Verekitug for COPD
The VENTURE trial explores a new TSLP receptor antagonist with potential for less frequent dosing and improved efficacy. Verekitug could be a game changer in moderate-to-severe COPD.
🌍 PAHO Launches Interactive Respiratory Virus Dashboard
This multilingual platform tracks influenza, RSV, and SARS-CoV-2 across the Americas with weekly updates, empowering public health professionals with real-time respiratory surveillance.
🧫 BiomX Reports 500-Fold Bacterial Reduction in CF Phage Therapy Trial
BX004, a novel phage cocktail, showed dramatic reductions in Pseudomonas aeruginosa burden in cystic fibrosis patients—without resistance or microbiome disruption. Phase 2b results expected in early 2026.
🇨🇳 China Advances COPD Treatment with Borui Pharma
Borui Pharma secures approval to begin trials of its tiotropium bromide aerosol for COPD. Despite a slight decline in profits last year, the move underscores China’s growing footprint in complex inhalation therapies as its domestic COPD market rapidly expands
🧬 Boehringer Launches Phase 3 AIRTIVITY® Trial for Bronchiectasis
BI 1291583 targets cathepsin C to reduce inflammation at the root cause of bronchiectasis. The Phase 3 trial follows strong efficacy signals from earlier studies.
💰 Merck Acquires Verona Pharma in $10 Billion Deal
Merck expands its respiratory pipeline by acquiring Ohtuvayre® (ensifentrine), a first-in-class FDA-approved COPD therapy combining bronchodilation and anti-inflammatory benefits.
📢 Stay Ahead in Respiratory and Pulmonary Health Research!
✅ Like, share, and subscribe for weekly updates on respiratory health breakthroughs
#RespiratoryHealth #COPDResearch #PhageTherapy #CysticFibrosis #PulmonaryInnovation #LupinPharma #VeronaPharma #MerckNews #Ohtuvayre #BX004 #TSLPBlockade #RespiratoryDashboard #BoehringerIngelheim #Bronchiectasis #LungHealth #ChinaBiotech #PulmonaryUpdates #BiotechNews #ClinicalTrials #HealthcareConsulting #LucidQuestHealth